Compare AROW & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROW | VOR |
|---|---|---|
| Founded | 1851 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.8M | 562.6M |
| IPO Year | 1995 | 2021 |
| Metric | AROW | VOR |
|---|---|---|
| Price | $32.69 | $14.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $28.00 | ★ $64.78 |
| AVG Volume (30 Days) | 80.7K | ★ 566.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | ★ 49.72 | 2.86 |
| EPS | ★ 2.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.58 | N/A |
| Revenue Next Year | $5.21 | N/A |
| P/E Ratio | $12.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.72 | $0.13 |
| 52 Week High | $36.44 | $49.95 |
| Indicator | AROW | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 46.61 |
| Support Level | $31.33 | $14.04 |
| Resistance Level | $33.30 | $14.73 |
| Average True Range (ATR) | 1.08 | 1.24 |
| MACD | -0.21 | -0.09 |
| Stochastic Oscillator | 25.07 | 14.12 |
Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of company's revenue is interest income, fees, commission earned through its subsidiaries.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.